Eligible patients can save up to $5000 annually WITH NO MONTHLY LIMIT

VEMLIDY Co-pay Coupon Program

  • The VEMLIDY Co-pay Coupon Program will cover the out-of-pocket costs of VEMLIDY prescriptions for eligible adults with chronic HBV infection and compensated liver disease who have commercial insurance
  • Patients enrolled in a government healthcare program such as Medicare Part D or Medicaid are not eligible. This includes patients in the Medicare Part D coverage gap known as the “donut hole“
  • The VEMLIDY Co-pay Coupon Program will cover the out-of-pocket costs of VEMLIDY prescriptions up to a maximum of $5000 per year.
VEMLIDY® (tenofovir alafenamide) Co-pay Coupon Card
Hand holding VEMLIDY® (tenofovir alafenamide) co-pay card
Go To Patient Enrollment
VEMLIDY® (tenofovir alafenamide) Co-pay Coupon Card
Hand holding VEMLIDY® (tenofovir alafenamide) co-pay card

For multilingual assistance call: 1-877-627-0415 Monday–Friday, 9 am–8 pm ET


HELP ELIGIBLE PATIENTS WITH INSURANCE SUPPORT AND MEDICATION ACCESS PROGRAMS

Gilead Advancing Access®

The Gilead Advancing Access program provides information to help facilitate patient access to medication. Program resources are available to patients and their providers. In some cases, patient consent is required before Advancing Access can provide assistance.

Advancing Access can provide information on the following topics:

  • Benefits investigation
  • Prior authorization
  • Appeal process
  • Alternative funding
  • Patient assistance program
  • Co-pay Coupon Program enrollment

HELP YOUR PATIENTS ENROLL

Gilead Advancing Access® Program

For multilingual assistance call: 1-800-226-2056 Monday–Friday, 9 am–8 pm ET

IMPORTANT SAFETY INFORMATION

BOXED WARNING: POST TREATMENT SEVERE ACUTE EXACERBATION OF HEPATITIS B

  • Discontinuation of anti-hepatitis B therapy, including VEMLIDY, may result in severe acute exacerbations of hepatitis B. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy, including VEMLIDY. If appropriate, resumption of anti-hepatitis B therapy may be warranted.

Warnings and Precautions

  • Risk of Development of HIV-1 Resistance in HBV/HIV-1 Coinfected Patients: Due to this risk, VEMLIDY alone should not be used for the treatment of HIV-1 infection. Safety and efficacy of VEMLIDY have not been established in HBV/HIV-1 coinfected patients. HIV antibody testing should be offered to all HBV-infected patients before initiating therapy with VEMLIDY, and, if positive, an appropriate antiretroviral combination regimen that is recommended for HBV/HIV-1 coinfected patients should be used.
  • New Onset or Worsening Renal Impairment: Cases of acute renal failure and Fanconi syndrome have been reported with the use of tenofovir prodrugs. In clinical trials of VEMLIDY, there have been no cases of Fanconi syndrome or proximal renal tubulopathy (PRT). Patients with impaired renal function and/or taking nephrotoxic agents (including NSAIDs) are at increased risk of renal-related adverse reactions. Discontinue VEMLIDY in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome. Monitor renal function in all patients – See Dosage and Administration.
  • Lactic Acidosis and Severe Hepatomegaly with Steatosis: Fatal cases have been reported with the use of nucleoside analogs, including tenofovir DF. Discontinue VEMLIDY if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity develop, including hepatomegaly and steatosis in the absence of marked transaminase elevations.

Adverse Reactions

Most common adverse reactions (incidence ≥5%; all grades) were headache, abdominal pain, cough, back pain, fatigue, nausea, arthralgia, diarrhea, and dyspepsia.

Drug Interactions

  • Coadministration of VEMLIDY with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of tenofovir and the risk of adverse reactions.
  • Coadministration of VEMLIDY is not recommended with the following: oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, or St. John’s wort. Such coadministration is expected to decrease the concentration of tenofovir alafenamide, reducing the therapeutic effect of VEMLIDY. Drugs that strongly affect P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) activity may lead to changes in VEMLIDY absorption.

Consult the full prescribing information for VEMLIDY for more information on potentially significant drug interactions, including clinical comments.

Dosage and Administration

  • Testing Prior to Initiation: HIV infection.
  • Prior to or when initiating, and during treatment: On a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus.
  • Dosage in Adults: 1 tablet taken once daily with food.
  • Renal Impairment: Not recommended in patients with end stage renal disease (ESRD; eCrCl <15 mL/min) who are not receiving chronic hemodialysis; in patients on chronic hemodialysis, on hemodialysis days, administer VEMLIDY after completion of hemodialysis treatment.
  • Hepatic Impairment: Not recommended in patients with decompensated (Child-Pugh B or C) hepatic impairment.

INDICATION

VEMLIDY is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.

Please click here to see full Prescribing Information for VEMLIDY, including BOXED WARNING.